BioSpace News Archive

Drug Development

Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level

Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.

January 3, 2022
·
4 min read
·
Gail Dutton
How to Combat Return to Work Anxiety After the Holiday Season

Can’t work due to return-to-work anxiety after the holiday season? Here are the top 10 tips to combat and manage and cope with the return to work anxiety.

January 3, 2022
·
5 min read
·
Alina Zahid
Drug Development

Spero, CStone Among First to Score NDA Approvals This Year

Today, the FDA approved two new drug applications. One is for Spero’s tebipenem HBr oral tablets and the second is CStone’s IND application for CS5001.

January 3, 2022
·
2 min read
·
Vanessa Doctor, RN
FDA

FDA Wraps Up 2021 with One Last Approval and Mesoblast Meeting

Just as 2021 was wrapping up, the U.S. FDA had some end-of-year activity. Here’s a look.

January 3, 2022
·
2 min read
·
Mark Terry
Drug Development

Will Novavax Vaccine for COVID-19 be able Cross the Finish Line in 2022?

Novavax vaccine’s emergency use authorization application has been submitted to FDA recently. Novavax is hoping to bring it to the Finish Line in 2022.

January 3, 2022
·
2 min read
·
Alex Keown
Business

AstraZeneca and Ovid Therapeutics Team Up Against Epilepsy

Data from pre-clinical studies show that OV350 may be developed to treat multiple types of epilepsy and other CNS conditions, including neurodevelopmental diseases.

January 3, 2022
·
2 min read
·
Vanessa Doctor, RN
Biotech Beach

Amberstone Biosciences Emerges with $12 Million for Solid Tumor Therapies

With $12 million in hand from a Series A investment round, Amberstone Biosciences aims at cancer with its highly-differentiated tumor microenvironment-activated therapeutic programs.

January 3, 2022
·
2 min read
·
Alex Keown
Business

Kyverna Tries NIH Cell Therapy for Autoimmune Disease

This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.

January 3, 2022
·
2 min read
·
Kate Goodwin
Lone Star Bio

FDA Okays Pfizer/BioNTech Booster for Adolescents and a Patent-Free Vaccine

Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.

January 3, 2022
·
7 min read
·
Mark Terry
Growth Hormone Drug Market Size, Share, Growth, Analysis By Application, By Route of Administration, By End-use And Forecast to 2028

January 3, 2022
·
1 min read